cabozantinib,atezolizumab
exelixis,roche
['atezolizumab', 'cabozantinib', 'urothelial']
failure of leap to meet primary endpoints colour the interpretation of cabozantinib + atezolizumab trial in urothelial cancer. is this different combination showing enough to study further? #asco2022 
An Australian oncologist with an interest in GU malignancies, phase 1 trials, cycling and having fun with the family